AzTrials
AzTrials

AlcoholismExZACTONCT01899521

Examination of Zinc, S-adenosylmethionine, and Combination Therapy Versus Placebo in Alcoholics

A study testing Bronchoscopy, Zinc sulfate 220 mg once daily and S-adenosylmethionine 400 mg twice daily in people with Alcoholism, run by VA Office of Research and Development at 1 site in United States.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

This is a randomized, placebo controlled trial of dietary zinc and S-adenosylmethionine (SAMe) in otherwise healthy alcoholic US Veterans. The primary goal is to determine if either dietary zinc or S-adenosylmethionine (SAMe) can augment lung immune defenses in alcoholics and thereby decrease the risk of lung injury… Read more about this study

Who is it for?
Ages 18 to 60 years
Conditions the study is for
Alcoholism
What is being tested?
Bronchoscopy, Zinc sulfate 220 mg once daily and S-adenosylmethionine 400 mg twice daily
Could I receive a placebo?
Yes, some participants may receive a placebo
How many people
113 participants
Where
1 siteUnited States
Study dates
1 May 2013to 31 Jul 2017
Phase
Interventional
Are there results?
Yes, posted in the registrySummary in the doctors' view

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 to 60 years
  • All sexes
  • No healthy volunteers
  • Adult

Who may be able to join

  • Age 18-60 years
  • Active alcohol use disorder

Who cannot join

  • Any active and uncontrolled medical problem(s)
  • Known zinc deficiency
  • Primary substance of abuse something other than alcohol
  • Current abnormal chest x-ray
  • HIV-positive
  • Any disorder of blood coagulation
Show all 19Show fewer
  • Currently on medical treatment with anti-coagulants, including:
  • warfarin
  • heparin
  • direct thrombin inhibitors
  • anti-platelet agents (other than Aspirin)
  • Daily use of vitamins or other nutritional supplements (unless taking as treatment for alcohol use disorder)
  • Renal impairment (GFR < 60)
  • Active bipolar disorder
  • Active Parkinson's disease
  • Current pregnancy
  • Contraindication to treatment with zinc or S-adenosylmethionine
  • Inability to give informed consent (i.e., limited cognitive capacity)
  • Non-English speaking

Trial locations and contacts

1 site in 1 country.

United States1 site
  • Atlanta VA Medical and Rehab Center, Decatur, GA

    Decatur, Georgia, 30033

Other trials in United States

About this study

Official title: Alcohol Abuse, Oxidative Stress, and Zinc Deficiency in Lung Disease

This is a randomized, placebo controlled trial of dietary zinc and S-adenosylmethionine (SAMe) in otherwise healthy alcoholic US Veterans. The primary goal is to determine if either dietary zinc or S-adenosylmethionine (SAMe) can augment lung immune defenses in alcoholics and thereby decrease the risk of lung injury and infection.

Read the detailed description

Alcohol abuse is a major burden on society and even more of a problem in the Veteran population. Chronic alcohol ingestion can have serious health consequences including pneumonia and acute lung injury, which can occur suddenly and without warning even in physically fit individuals without apparent signs of alcohol dependence. Therefore, it is vital for the health of our Veterans and indeed the entire population to identify effective treatments that can limit or even prevent these devastating consequences. The primary goal of this clinical research project is to determine if dietary zinc or supplements of the antioxidant S-adenosylmethionine (SAMe) can augment lung immune defenses in otherwise healthy alcoholics and thereby decrease the risk of lung injury and infection. There is already strong evidence from the investigators' experimental animal model that moderate daily alcohol ingestion for as little as six weeks causes oxidative stress and zinc deficiency in the lung. These derangements result insult in dysfunction of the alveolar macrophage, which is the resident immune cell, and predisposes animals to the development of pneumonia. Importantly, in this same animal model, the investigators found that adding either zinc or antioxidants to the diet prevents these problems and preserves lung health even during daily alcohol ingestion.

This project will translate basic findings in the animal model to the clinical setting and determine whether or not zinc or SAMe supplements are effective in humans who pathologically consume alcohol. This project will enroll Veterans seen at the Atlanta Veterans Hospital in the Substance Abuse Treatment Program (SATP). Participants will be evaluated by undergoing a procedure to obtain samples of fluid from their lungs, measure zinc levels, redox potential, and assess how well their alveolar macrophages respond to bacteria (by determining phagocytic capacity). After completion of the initial evaluation, the participants will be randomized to receive standard treatment (placebo), zinc supplements, dietary SAMe, or the combination of zinc and SAMe for 14 days. All subjects will be evaluated for two weeks as they undergo treatment. At the end of this two week period, measurements of lung zinc, redox potential and macrophage function will be repeated and compared between the two groups. The hypothesis is that both dietary zinc and SAM supplements will improve the immune function of the alveolar macrophage.

If this project is successful, it will lead to larger clinical trials to determine if either dietary zinc and/or SAMe supplements can be effective even in the acute clinical setting and improve outcomes in alcoholics who develop pneumonia or acute lung injury. Overall, both zinc and SAMe supplements are safe and inexpensive to provide, allowing these potential treatments to be easily implemented in the Veteran population as well as society in general. Given the significant burden of unhealthy alcohol use, the investigators need ways to limit the physical consequences of alcohol abuse while the investigators continue the efforts at public education and addiction treatment.

Conditions
Alcoholism
Being tested
Bronchoscopy, Zinc sulfate 220 mg once daily, S-adenosylmethionine 400 mg twice daily
Keywords
alcoholism, lung health, pulmonary, macrophage, zinc, SAMe, S-adenosylmethionine, alveolar
Medical subject headings
Alcoholism

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • BronchoscopyProcedure or surgery

    Involves flexible fiberoptic bronchoscopy with standardized bronchoalveolar lavage (BAL) technique (isotonic saline in a sub-segment of the right middle lobe or lingula) using standard conscious sedation techniques.

  • Zinc sulfate 220 mg once dailyDietary supplement

  • S-adenosylmethionine 400 mg twice dailyDietary supplement

    Also called SAMe

Study groups in NCT01899521
Study groupRoleWhat they receive
Placebo zinc and placebo SAMePlacebo comparatorPlacebo tablet of zinc sulfate once daily and placebo tablet of s-adenosylmethionine twice daily
Receives: Procedure: Bronchoscopy
Active zinc and placebo SAMeActive comparatorZinc sulfate 220 mg once daily and placebo tablet of s-adenosylmethionine twice daily
Receives: Procedure: Bronchoscopy; Dietary Supplement: Zinc sulfate 220 mg once daily
Placebo zinc and active SAMeActive comparatorPlacebo tablet of zinc sulfate once daily and s-adenosylmethionine 400 mg twice daily
Receives: Procedure: Bronchoscopy; Dietary Supplement: S-adenosylmethionine 400 mg twice daily
Active zinc and active SAMeActive comparatorZinc sulfate 220 mg once daily and s-adenosylmethionine 400 mg twice daily
Receives: Procedure: Bronchoscopy; Dietary Supplement: Zinc sulfate 220 mg once daily; Dietary Supplement: S-adenosylmethionine 400 mg twice daily

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Primary Endpoint

    Improvement in alveolar macrophage phagocytic index. Phagocytic index will be measured before and after treatment phase. Phagocytic index is calculated using isolated alveolar macrophages from the bronchoscopy procedure such that phagocytic index = (total number of engulfed cells/total number of counted macrophages) x (number of macrophages containing engulfed cells/total number of counted macrophages) x 100.

    Measured: Initial bronchoscopy to second bronchoscopy (Initial bronchoscopy performed prior to treatment and second bronchoscopy done 2-3 weeks after starting treatment)

Secondary outcomes (1)
  1. Secondary Endpoint

    Improvement in alveolar macrophage intracellular zinc. Intracellular zinc will be measured before and after treatment phase using isolated alveolar macrophages. The units of measure are relative fluorescence units/cell (RFU/cell) and measured using confocal microscopy techniques.

    Measured: Initial bronchoscopy to second bronchoscopy (Initial bronchoscopy performed prior to treatment and second bronchoscopy done 2-3 weeks after starting treatment)

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted15 Jul 2013 (estimated)
  2. Study start1 May 2013
  3. Primary completion31 Jul 2017
  4. Study completion31 Jul 2017

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Treatment
Allocation
Randomised
Intervention model
Parallel groups
Masking
Triple blind
Who is masked
Participant, Care provider, Investigator
Enrolment
113 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT01899521
Sponsor's protocol ID
PULM-038-12S
Other IDs
IRB00060773, IK2CX000643
Acronym
ExZACTO
Status last verified
Aug 2024
First submitted
27 Jun 2013
Last updated
19 Sep 2024
Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
Undecided

Questions about this trial

What is this clinical trial studying?

A study testing Bronchoscopy, Zinc sulfate 220 mg once daily and S-adenosylmethionine 400 mg twice daily in people with Alcoholism, run by VA Office of Research and Development at 1 site in United States.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 2 inclusion and 19 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 19 Sep 2024. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

Yes. Results are posted in the registry (first posted 19 Sep 2024). A summary is in the For doctors view, and the full results are on ClinicalTrials.gov.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Primary Endpoint (time frame: Initial bronchoscopy to second bronchoscopy (Initial bronchoscopy performed prior to treatment and second bronchoscopy done 2-3 weeks after starting treatment)). It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 19 Sep 2024.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in